How have CYTO shares performed in 2023?

Altamira Therapeutics' stock was trading at $4.85 at the beginning of 2023. Since then, CYTO stock has decreased by 92.5% and is now trading at $0.3620. View the best growth stocks for 2023 here .

Are investors shorting Altamira Therapeutics?

Altamira Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average daily trading volume, of 8,950,000 shares, the days-to-cover ratio is presently 0.1 days. View Altamira Therapeutics' Short Interest .

When did Altamira Therapeutics' stock split?

Altamira Therapeutics shares reverse split before market open on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Altamira Therapeutics' major shareholders?

Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%).

How do I buy shares of Altamira Therapeutics?

Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Altamira Therapeutics Stock Price, News & Analysis (NASDAQ:CYTO)

$0.44

+0.08 (+20.88%)

(As of 09:04 AM ET)

Compare

Today's Range: $0.44
▼
$0.44
50-Day Range: $0.10
▼
$0.64
52-Week Range: $0.09
▼
$5.99

Volume: 4.86 million shs
Average Volume: 4.48 million shs
Market Capitalization: $3.06 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Stock Analysis Chart Competitors Financials Headlines Ownership SEC Filings Short Interest Social Media

About Altamira Therapeutics Stock (NASDAQ:CYTO)

Altamira Therapeutics Ltd., a clinical-and commercial-stage biopharmaceutical company, engages in the development of therapeutics that address various unmet medical needs in Switzerland, the United States, Europe, and Australia. The company develops OligoPhore/SemaPhore, a platform for delivery of oligonucleotides, such as small interfering ribonucleic acid or messenger RNA into target cells. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens. The company is also developing AM-401 for the treatment of KRAS driven cancer; AM-411 for the treatment of rheumatoid arthritis; AM-125 that is in phase II clinical trial for the treatment of vertigo; Keyzilen, which is in phase III clinical trial for the treatment of acute inner ear tinnitus; and Sonsuvi that is in phase III of clinical development for the treatment of acute inner ear hearing loss. The company was formerly known as Auris Medical Holding Ltd. and changed its name to Altamira Therapeutics Ltd. in July 2021. The company was founded in 2003 and is headquartered in Hamilton, Bermuda.

CYTO Stock Price History

30 days | 90 days | 365 days | Advanced Chart

CYTO Stock News Headlines

December 5, 2023 | finance.yahoo.com

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

December 5, 2023 | finance.yahoo.com

Altamira Therapeutics to Host Investor & Business Update Call on December 11th

December 6, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

December 5, 2023 | benzinga.com

Thinking about buying stock in Macy's Inc, Altamira Therapeutics, Neurosense Therapeutics, Cytosorbents, or Designer Brands?

November 29, 2023 | finance.yahoo.com

Altamira Therapeutics Regains Compliance with Nasdaq Minimum Stockholders' Equity Requirement

November 20, 2023 | uk.finance.yahoo.com

November 17, 2023 | msn.com

Altamira stock surges after deal to sell 51% stake in Medica

November 17, 2023 | msn.com

Why Is Altamira Therapeutics (CYTO) Stock Up 160% Today?

December 6, 2023 | Edge On The Street (Ad)

Americans Now Favor Gold Over Stocks as an Investment Vehicle

Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.

November 17, 2023 | marketwatch.com

Altamira Therapeutics Shares Surge on Sale of Bentrio Unit

November 17, 2023 | finance.yahoo.com

Altamira Therapeutics Announces Partial Spin-Off of Bentrio® Business

November 10, 2023 | finance.yahoo.com

Altamira Therapeutics Announces European Patent Office Decision to Grant for Patent Application Covering Intranasal Betahistine

November 3, 2023 | msn.com

Why Is Altamira Therapeutics (CYTO) Stock Up 28% Today?

September 14, 2023 | marketwatch.com

Altamira Therapeutics Shares Rise on Positive Bentrio Trial Results

September 14, 2023 | finance.yahoo.com

Altamira Therapeutics Reports Additional Significant Efficacy Outcomes from Bentrio Clinical Trial in Seasonal Allergic Rhinitis

September 13, 2023 | insidermonkey.com

Altamira Therapeutics Ltd. (NASDAQ:CYTO) Q2 2023 Earnings Call Transcript

September 12, 2023 | finanznachrichten.de

Altamira Therapeutics Ltd: Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

September 12, 2023 | finance.yahoo.com

Altamira Therapeutics Provides Business Update and First Half 2023 Financial Results

September 8, 2023 | markets.businessinsider.com

Altamira Therapeutics Ltd Registered Shs hosts conference call for investors

September 6, 2023 | finance.yahoo.com

Altamira Therapeutics to Host First Half 2023 Financial Results and Business Update Call on September 12th

August 23, 2023 | uk.finance.yahoo.com

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

August 23, 2023 | finance.yahoo.com

Altamira Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference September 11-13

July 20, 2023 | finance.yahoo.com

Altamira Therapeutics and Pharma Nordic Collaborate for Marketing and Distribution of Bentrio in Scandinavia

July 17, 2023 | finance.yahoo.com

Altamira Therapeutics Announces Publication of Positive Results from Clinical Trial with Bentrio in House Dust Mite Allergy in Leading Peer Reviewed Journal

July 6, 2023 | msn.com

Why Altamira Therapeutics (CYTO) Stock Is Getting Hammered

July 6, 2023 | finance.yahoo.com

Altamira Therapeutics Announces Pricing of $5.0 Million Public Offering

July 5, 2023 | finance.yahoo.com

Altamira Therapeutics Announces Collaboration with Heqet Therapeutics on Nanoparticle-Delivered Non-Coding RNAs for Cardiac Regeneration

See More Headlines

Receive CYTO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altamira Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today: 12/06/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:CYTO
CUSIP: N/A
CIK: 1601936
Web: www.aurismedical.com
Phone: (441) 295-5950
Fax: 41-61-201-1351
Employees: 16
Year Founded: N/A

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: N/A
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: N/A
Return on Assets: N/A

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 0.32
Quick Ratio: 0.27

Sales & Book Value

Annual Sales: $120,287.00
Price / Sales: 21.03
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: ($7.38) per share
Price / Book: -0.05

Miscellaneous

Outstanding Shares: 6,989,000
Free Float: 6,078,000
Market Cap: $2.53 million
Optionable: Not Optionable
Beta: 1.69

7 AI Stocks to Invest In: An Introduction to AI Investing For Self-Directed Investors

As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.

Get This Free Report

Key Executives

Dr. Thomas Meyer Ph.D. (Age 55)
Founder, Chairman, CEO & MD
Comp: $566.88k
Mr. Marcel Gremaud CPA (Age 65)
Chief Financial Officer
Dr. Covadonga Paneda (Age 49)
Chief Operating Officer
Dr. Samuel A. Wickline M.D. (Age 70)
Chief Scientific Adviser

Key Competitors

View All Competitors

Institutional Ownership

Armistice Capital LLC
Bought 829,000 shares on 11/15/2023
Ownership: 11.860%

View All Institutional Transactions

CYTO Stock Analysis - Frequently Asked Questions

How have CYTO shares performed in 2023?: Altamira Therapeutics' stock was trading at $4.85 at the beginning of 2023. Since then, CYTO stock has decreased by 92.5% and is now trading at $0.3620.
View the best growth stocks for 2023 here.
Are investors shorting Altamira Therapeutics?: Altamira Therapeutics saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 514,300 shares, an increase of 181.5% from the October 31st total of 182,700 shares. Based on an average daily trading volume, of 8,950,000 shares, the days-to-cover ratio is presently 0.1 days.
View Altamira Therapeutics' Short Interest.
When did Altamira Therapeutics' stock split?: Altamira Therapeutics shares reverse split before market open on Tuesday, October 25th 2022. The 1-20 reverse split was announced on Tuesday, October 25th 2022. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, October 25th 2022. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Who are Altamira Therapeutics' major shareholders?: Altamira Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Armistice Capital LLC (11.86%) and Concourse Financial Group Securities Inc. (0.00%).
How do I buy shares of Altamira Therapeutics?: Shares of CYTO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:CYTO) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial